Here are the latest G-BA decisions from the G-BA meeting held on 16 April 2026 on the early benefit assessments of Romvimza, Kisunla, Omjjara and Ayvakyt.
A database of all previous G-BA resolutions is available in my store.
- Romvimza (vimseltinib); Symptomatic tenosynovial giant cell tumours – Orphan drug, Indication of considerable additional benefit
- Kisunla (donanemab); Early Alzheimer’s disease – Additional benefit not proven in both subgroups
- Omjjara (momelotinib); Myelofibrosis – Reassessment of an orphan drug after exceeding the €30 million threshold; Additional benefit not proven in both subgroups
- Ayvakyt (avapritinib); Reassessment of an orphan drug after exceeding the €30 million threshold:
- Advanced systemic mastocytosis, after at least one prior therapy – Additional benefit not proven
- Gastrointestinal stromal tumours – Additional benefit not proven